SCHEMBL2195568

SCHEMBL2195568

Cc1ccc(CN(I)I)cc1.Cn1cc(-c2ccccc2)n(C)c1=[Pt]

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 1/20 0.36
CYP2C19 P33261 2/20 0.35
NPC1 O15118 2/20 0.34
RAB9A P51151 2/20 0.34
TAAR1 Q96RJ0 1/20 0.33
HTT P42858 2/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
CYP1A2 P05177 2/20 0.32
CYP3A4 P08684 2/20 0.32
SMN1; SMN2 Q16637 2/20 0.32
CYP2C9 P11712 1/20 0.32
TP53 P04637 4/20 0.31
LMNA P02545 2/20 0.31
POLB P06746 1/20 0.31
TSHR P16473 1/20 0.31
NR4A2 P43354 1/20 0.31
DCTPP1 Q9H773 1/20 0.31
PTGES O14684 1/20 0.31
ALOX5 P09917 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2197714 0.92 GAA (0.34) TAAR1MEN1KMT2ACYP1A2CYP3A4
SCHEMBL2193567 0.89 CYP11B1 (0.36) CYP19A1NPC1TAAR1MEN1KMT2A
SCHEMBL2195162 0.86 LMNA (0.34) HTTMEN1KMT2ALMNA
SCHEMBL2195071 0.85 CYP19A1 (0.36) CYP19A1NPC1RAB9AMEN1KMT2A
SCHEMBL2195697 0.85 TP53 (0.38) CYP19A1CYP2C19NPC1RAB9AHTT
SCHEMBL2197023 0.81 CYP19A1 (0.39) CYP19A1CYP2C19NPC1RAB9ATAAR1
SCHEMBL2192014 0.78 HPGDS (0.34) CYP3A4SMN1; SMN2LMNATSHRMAPT
SCHEMBL2196788 0.78 CYP2C19 (0.36) CYP19A1CYP2C19MEN1KMT2ACYP1A2
SCHEMBL2196154 0.76 CNR2 (0.38) CYP19A1MEN1KMT2ASMN1; SMN2LMNA
SCHEMBL2195473 0.75 ALDH1A1 (0.39) CYP19A1HTTMEN1KMT2ACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8980875-B2 Platinum-N-heterocyclic carbene derivatives, preparation thereof and therapeutic use thereof CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2015-03-17 US claimed
US-20130338128-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2013-12-19 US claimed
US-8481522-B2 Platinum-N-heterocyclic carbene derivatives, preparation thereof and therapeutic use thereof SANOFI (FR) 2013-07-09 US claimed
US-20110172199-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2011-07-14 US claimed
US-20110172199-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2011-07-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130338128-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SCO2, C3AR1, IDH1 CYP19A1 787/4885CYP2C19 255/4885NPC1 3384/4885
US-20110172199-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SCO2, C3AR1, IDH1 CYP19A1 787/4885CYP2C19 255/4885NPC1 3384/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.